Muscle spasticity
Drug research and approvals for muscle spasticity: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 106 studies of muscle spasticity are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 106
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Effects of Instrument-Assisted Soft Tissue Mobilization (IASTM) Along With Conventional Physical Therapy on Upper Limb…NCT07937098 · Not applicable · Ibadat International University, Islamabad · starts Jul 9, 2026
- Short-Term Effects of Manual Therapy Prior to Neuromotor Therapy in Children With Cerebral PalsyNCT07902466 · Not applicable · LIFE - Research and Care Institute - Santa Lucia IRCCS · starts Oct 15, 2026
- Extracorporeal Shockwave Therapy as an Additional Treatment for Spasticity Secondary to Spinal Cord InjuryNCT07894991 · Phase 2 · Kessler Foundation · starts Sep 21, 2026
- Addressing Spasticity and Motor Function With Epidural Spinal Cord StimulationNCT07890558 · Not applicable · Kessler Foundation · starts Nov 1, 2026
- Rare Disease Registry Database for Movement Disorders in Southern Anhui ProvinceNCT07838883 · Not reported · First Affiliated Hospital of Wannan Medical College · starts Sep 30, 2026
- Short-term Spinal Stimulation Effects in Cerebral PalsyNCT07826494 · Not applicable · University of Washington · starts Aug 13, 2026
- Outcomes of Neurosurgical Tone ManagementNCT07817745 · Not reported · Boston Children's Hospital · starts Jun 26, 2024
- The Use of Photobiomodulation in the Treatment of Spasticity After Stroke.NCT07784231 · Phase 1 / Phase 2 · University of Nove de Julho · starts Aug 28, 2026
- Effectiveness of Modified Constraint-Induced Movement Therapy Versus Mirror Therapy in Spastic Hemiplegic Cerebral…NCT07747974 · Not applicable · Ibadat International University, Islamabad · starts Mar 3, 2026
Approved 4
- BaclofenGABA-B receptor agonist
- TizanidineAdrenergic receptor alpha-2 agonist
- DantroleneRyanodine receptor 1 antagonist
- CyclobenzaprineSerotonin 2a (5-HT2a) receptor antagonist
Phase 3 5
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- IncobotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- ArbaclofenGABA-B receptor agonist
- DalfampridineVoltage-gated potassium channel blocker
- Cannabinol
Phase 2 6
- Tolperisone
- RimabotulinumtoxinbVesicle-associated membrane protein 2 inhibitor
- MoxifloxacinTopoisomerase IV inhibitor
- NabiloneCannabinoid CB1 receptor agonist
- SelurampanelGlutamate receptor ionotropic AMPA antagonist
- Arbaclofen placarbilGABA-B receptor agonist
How its trials ended
634 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 106 whose ending is known, 55% met their primary endpoint, 4% missed it and 42% stopped early.
- Completed, result not reported29346%
- Ongoing14523%
- Status unknown9014%
- Met its primary endpoint589%
- Stopped: other or unclear244%
- Stopped: enrollment or feasibility132%
- Missed its primary endpoint41%
- Stopped: sponsor or business decision41%
- Stopped: lack of efficacy3<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA